ProKidney Corp. (PROK) stock
PROKNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$1.15+0.02 (+1.77%)
Close on Nov 12, 2026Market cap $347.67MP/E –Yield –
ProKidney ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
ProKidney's ebitda for the twelve months ending Sep 30, 2026 was -$185.59M. For fiscal 2025 it was -$158.43M. The highest annual figure on record is -$26.06M in fiscal 2020.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$158.43M | – |
| FY2024 | Dec 31, 2024 | -$178.24M | – |
| FY2023 | Dec 31, 2023 | -$147.67M | – |
| FY2022 | Dec 31, 2022 | -$149.97M | – |
| FY2021 | Dec 31, 2021 | -$53.13M | – |
| FY2020 | Dec 31, 2020 | -$26.06M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$52.09M | – |
| Q2 FY2026 | Jun 30, 2026 | -$46.70M | – |
| Q1 FY2026 | Mar 31, 2026 | -$43.28M | – |
| Q4 FY2025 | Dec 31, 2025 | -$43.53M | – |
| Q3 FY2025 | Sep 30, 2025 | -$36.87M | – |
| Q2 FY2025 | Jun 30, 2025 | -$38.24M | – |
| Q1 FY2025 | Mar 31, 2025 | -$39.79M | – |
| Q4 FY2024 | Dec 31, 2024 | -$50.00M | – |
| Q3 FY2024 | Sep 30, 2024 | -$47.49M | – |
| Q2 FY2024 | Jun 30, 2024 | -$41.79M | – |
| Q1 FY2024 | Mar 31, 2024 | -$38.97M | – |
| Q4 FY2023 | Dec 31, 2023 | -$23.06M | – |
| Q3 FY2023 | Sep 30, 2023 | -$45.61M | – |
| Q2 FY2023 | Jun 30, 2023 | -$38.95M | – |
| Q1 FY2023 | Mar 31, 2023 | -$40.04M | – |
| Q4 FY2022 | Dec 31, 2022 | -$29.44M | – |
| Q3 FY2022 | Sep 30, 2022 | -$34.79M | – |
| Q2 FY2022 | Jun 30, 2022 | -$19.99M | – |
| Q1 FY2022 | Mar 31, 2022 | -$65.75M | – |
| Q4 FY2021 | Dec 31, 2021 | -$13.12M | – |
See a number that looks wrong?